Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8820637 | Revue des Maladies Respiratoires Actualités | 2017 | 5 Pages |
Abstract
Innovative treatments which have demonstrated activity in advanced disease have been evaluated in the perioperative setting. Antiangiogenic agents have no interest in this situation. Studies of EGFR tyrosine kinase inhibitors in all-comers are negative. The first phase lll results of adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutated tumors are promising. Preliminary data of immune checkpoint inhibitors given as neoadjuvant therapy highly justify further study. Several ongoing large trials should help to better define the place of these agents within the future therapeutic perioperative panel.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
V. Westeel,